ReviewAntioxidants (Basel, Switzerland)2026
Oxidative Stress Biomarkers in Pediatric and Early-Stage Type 1 Diabetes: Toward Redox Phenotyping.
Review in Antioxidants (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) is characterized by autoimmune β-cell destruction, metabolic instability, and long-term susceptibility to vascular and renal complications. Oxidative stress has been widely implicated in these processes, but it is often described as a generalized consequence of hyperglycemia, not as a measurable and heterogeneous biological state. In this review, we propose exploratory redox phenotyping as a framework for characterizing oxidative stress in pediatric and early-stage T1D. This approach integrates biomarkers of antioxidant defense, lipid peroxidation, protein oxidation, DNA oxidation, and inflammation-associated redox activity to explore potentially distinct patterns of redox dysregulation. Key biomarker domains include enzymatic antioxidant systems, lipid-peroxidation products, protein- and DNA-oxidation markers, and inflammatory mediators, which may collectively characterize the intensity, molecular compartment, and possible clinical relevance of redox dysregulation. Across pediatric presymptomatic T1D, newly diagnosed disease, partial remission, and short-duration established T1D, longitudinal redox profiling may help distinguish stage-specific or transient metabolic responses from persistent oxidative dysregulation. These clinical phases are considered separately as they differ in immune activity, residual C-peptide secretion, glycemic exposure, and biological susceptibility. Redox phenotyping may also improve the design of antioxidant, mitochondrial, anti-inflammatory, and NRF2-targeted interventions by enabling biomarker-based patient selection. By defining oxidative stress as a stratifiable biological domain, this framework may advance precision risk assessment and guide more rational, targeted redox-directed therapies for children and individuals with early-stage T1D. At present, these proposed profiles remain hypothetical and require validation in prospective cohorts using standardized assays, reproducible thresholds, and clinically meaningful outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.